SAT0209 A comparative real-world utilization patterns of innovator and biosimilar infliximab in a treatment naÏve and switch population from germany: a prescription claims analysis. (12th June 2018)

• Record Type: Journal Article
• Authors: Ewara, E. M.; Ellis, L.; Goyal, K.; Jairath, V.; Marrache, A. M.; Baraliakos, X.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 965
• Page End: 965
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.1327
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Data on treatment utilization patterns for innovator infliximab (IFX) and biosimilar infliximab (CT-P13) in IBD are scarce. Given low uptake of biosimilars in Canada to date, evaluation of treatment initiation and discontinuation was undertaken in a proxy country, Germany, which has similar demographic factors and neither have a mandated biosimilar switch policy. Objectives: Retrospective prescription claims analysis comparing utilization patterns of innovator (IFX) and biosimilar (CT-P13) infliximab in treatment naïve population at 12 months and in patients continuing IFX vs switching to CT-P13 at 6 months. Methods: QuintilesIMS™ longitudinal health insurance prescription data from Germany identified patients with an index claim of IFX or CT-P13 in all indications between Feb 2015-Oct 2016. Twelve-month post-drug initiation and 6-month post innovator-to-biosimilar switch retention analyses were conducted. All patients had sufficient claims history post-index and ≥2 claims of IFX or CT-P13 within the analysis period. Six-month analyses included: 1) matched analysis where each CT-P13 switch patient was matched to 5 IFX patients for IFX exposure prior to switch; 2) unmatched analysis where CT-P13 switch patients were compared to the first 6 months of the IFX treatment naïve population. Log-binomial regression analyses were conducted to determine the relative risk (RR) of being retained on treatment at 6 or 12 months adjusted for age, sex, biologic treatment history and prescriber specialty. Results: 6, 491 patients had a claim of IFX or CT-P13. Of these, 1, 160 and 1, 324 patients had follow up time for inclusion in the 12-month naïve and 6-month post-switch analyses, respectively. Only IFX to CT-P13 switch utilization (n=101) was investigated. The risk adjusted probability of being retained on treatment after 12 months was 23% greater in the IFX group than in the CT-P13 group (RR IFX=1.23, 95% Confidence Interval [CI]: 1.12–1.36, p<0.0001). The probability of being retained was also greater in men, those who were bio-naive and those prescribed drug by a rheumatologist. In the matched 6 months post-switch analysis the risk adjusted probability of being retained on treatment was 26% greater in the IFX maintenance group than in the CT-P13 switch group (RR IFX=1.26, 95%CI: 1.10–1.45, p=0.0007). The probability of being retained was also greater in those prescribed drug by a rheumatologist. Similar results were found in the unmatched analysis (RR IFX =1.32, 95%CI: 1.16–1.51, p<0.0001), where the probability of being retained was also greater in men and in those who were bio-naïve. Conclusions: The findings from Germany demonstrate significant differences in the real-world utilization patterns of patients treated with IFX or CT-P13 in all labelled indications. Limitations of this study include a heterogenous population, disease severity and reasons for staying on treatment or switching could not be determined. Futrure analyses should capture clinical outcomes to better understand observed utilizatin patterns. Disclosure of Interest: E. Ewara Employee of: Janssen, L. Ellis Employee of: Janssen, K. Goyal Employee of: Janssen, V. Jairath Consultant for: Abbvie, Takeda, Shire, Janssen, Ferring, Sandoz, Speakers bureau: Ferring, Takeda, Shire, Janssen, A. M. Marrache Employee of: Janssen, X. Baraliakos: None declared